Kintara names Robert Hoffman as CEO; Saiid Zarrabian transitions to Head of Strategic Partnerships

TuHURA Biosciences, Inc./NV

Robert E. Hoffman appointed President and CEO effective Nov 8, 2021; previously Chairman.
Saiid Zarrabian steps down as CEO, becomes Head of Strategic Partnerships.
Hoffman receives $551k base salary, 3,519,170 stock option grant (4-yr vest), target bonus up to 50%.
Zarrabian's new salary $285k, target bonus up to 40%; unvested options now tied to milestones.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Robert E. Hoffman

President and Chief Executive Officer

HURA · TuHURA Biosciences, Inc./NV

Effective: 2021-11-08
Filed: November 12, 2021, 6:59 PM ET

On November 8, 2021, the Board of Directors (the “Board”) of Kintara Therapeutics, Inc. (the “Company”) appointed Robert E. Hoffman, the then current Chairman of the Board, to succeed Saiid Zarrabian as President and Chief Executive Officer of the Company.

Role change

Saiid Zarrabian

Head of Strategic Partnerships

HURA · TuHURA Biosciences, Inc./NV

Effective: 2021-11-08
Successor: Robert E. Hoffman
Filed: November 12, 2021, 6:59 PM ET

on November 8, 2021, the Board and Mr. Zarrabian mutually agreed that Mr. Zarrabian would immediately transition into the role of Head of Strategic Partnerships.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert E. Hoffman was appointed as President and Chief Executive Officer at TuHURA Biosciences, Inc./NV.

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

On November 8, 2021, the Board of Directors (the “Board”) of Kintara Therapeutics, Inc. (the “Company”) appointed Robert E. Hoffman, the then current Chairman of the Board, to succeed Saiid Zarrabian as President and Chief Executive Officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Saiid Zarrabian changed role as Head of Strategic Partnerships at TuHURA Biosciences, Inc./NV.

Action: transitioned
Role: Head of Strategic Partnerships

Exact text from the filing

on November 8, 2021, the Board and Mr. Zarrabian mutually agreed that Mr. Zarrabian would immediately transition into the role of Head of Strategic Partnerships.

View on SEC.gov

TuHURA Biosciences, Inc./NV filing history →

Source: SEC EDGAR

accession 0001564590-21-056375

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.